During the year, the DSG2D Network organises meetings for its members (also at the annual ECNP Congress).

TRISOMY21 cluster
Members of the DSG2D Network have contributed to the creation of the TRISOMY21 cluster recognised by the project EBRA (European Brain Research Agenda).

Research projects

  • Psych-STRATA — A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness
    Call: H2020. 26 partners from twelve countries, two members of the ECNP Network DSG2D
  • GO-DS21: Gene overdosage and comorbidities during the early lifetime in Down syndrome (OMICS in human and mouse models)
    Call: H2020-SC1-BHC-01-2019. 11 partners, 4 members of the ECNP Network DSG2D
  • PROMPT — Toward precision medicine for the prediction of treatment response in major depressive disorder through stratification of combined clinical and -omics signatures
    (EraPerMed Grant; in collaboration with ECNP TWG “Pharmacogenomics & Transcriptomics”)
  • HEROES (The locus coeruleus: at the crossroad of dementia syndromes)
    EU Joint Program — Neurodegenerative Disease Research (JPND) project
  • Neuropathological and Amyloid peptides differences between Down syndrome and familial Alzheimer’s disease with duplications and missense mutations in APP gene
    EU Joint Program — Neurodegenerative Disease Research (JPND) project

Recommended publications

Authors  Year Title  Journal and link to the article 
Faundez et al.
Translating molecular advances in Down syndrome and fragile X syndrome into therapies.                                        
European Neuropsychopharmacology
de la Torre et al. 2016
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology

Textbooks and more
“Preclinical Research in Down syndrome: from bench to bedside”, in the Progress in Brain Research series of Elsevier, 2020.

Other applications

  • PHC 13 – 2014: New therapies for chronic non-communicable diseases.
  • IDTHERA: Disease modifying avenues of intervention for Intellectual Disability (rejected at second stage).
  • PHC 3 - 2015: Understanding common mechanisms of diseases and their relevance in co-morbidities.
  • iTAD: Investigating common mechanisms in Trisomy 21 and Alzheimer’s disease (rejected at second stage).
  • ERANET- NEURON: REMBRANDT ReModelling BRAiN DevelopmenT in intellectual disability (rejected at second stage).
  • H2020-SC1-BHC-01-2019: GO-DS21: Gene Overdosage and Comorbidities During the Early Lifetime in Down Syndrome (OMICS in human and mouse models). Submitted in April 2019 (11 partners, 4 members of the ECNP Network DSG2D).

Targeted Network Meetings
'Common mechanisms and therapeutic avenues for Down syndrome and other genetic developmental disorder' (21 September 2016, Vienna, Austria).